Acetylcholine release from presynaptic cholinergic neuron

Acetylcholine release from presynaptic cholinergic neurons is a core process in both the central and peripheral nervous systems, essential for neurotransmission, modulation of neural circuits, and higher brain functions such as memory and cognition[5][4][2]. It occurs when action potentials arrive at presynaptic terminals, triggering exocytosis of acetylcholine-filled vesicles into the synaptic cleft. Released acetylcholine then binds to postsynaptic muscarinic and nicotinic receptors to propagate neuronal signaling[5][3]. Pharmacological modulation of this process is fundamental in the treatment of neurological disorders such as Alzheimer’s disease, primarily through inhibition of acetylcholinesterase to enhance acetylcholine availability[2]. As a therapeutic target, drugs typically modulate the process indirectly, and dysfunction of acetylcholine release can contribute to neurodegenerative and cognitive disorders[2][4]. This entry best serves as a functional/process-level annotation rather than as a canonical molecular target. If structured drug discovery information is required, consider referring to the specific molecular mediators—such as nicotinic acetylcholine receptor (nAChR), muscarinic acetylcholine receptor (mAChR), choline acetyltransferase (ChAT), or acetylcholinesterase (AChE)—as canonical targets[5][3][4].

Other names

Presynaptic acetylcholine releaseCholinergic neurotransmitter release

Cholinesterase inhibitors: Prevent breakdown of acetylcholine, increasing synaptic availability[2][5] Presynaptic agonists/antagonists: Increase or decrease acetylcholine release Neurotoxins (e.g., botulinum toxin): Inhibit synaptic vesicle exocytosis, blocking release